편두통 치료의 최신 지견An Update On Migraine Treatment
- Authors
- 문희수; 박광열; 정재면; 김병건
- Issue Date
- 2020
- Publisher
- 대한신경과학회
- Keywords
- Migraine disorders; Therapeutics; Guideline
- Citation
- 대한신경과학회지, v.38, no.2, pp 100 - 110
- Pages
- 11
- Journal Title
- 대한신경과학회지
- Volume
- 38
- Number
- 2
- Start Page
- 100
- End Page
- 110
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/42252
- DOI
- 10.17340/jkna.2020.2.3
- ISSN
- 1225-7044
- Abstract
- Globally, migraine is the third most common disease affecting 1.3 billion people worldwide and the second leading cause of disability. With the recent advances in new drugs and device technology for the treatment of migraine, the Korean Headache Society (KHS) and American Headache Society (AHS) released a new practice guideline on the treatment of migraine in 2019, respectively. They developed their consensus statement after reviewing existing guidelines and recent clinical trials and having discussions with stakeholders. The KHS guideline addresses best practice for preventing migraine with oral treatments including start and stopping strategies. The AHS statement dealt with newer treatments, such as onabotulinumtoxinA, and the recently approved calcitonin gene-related peptide targeting agents, and nonpharmacological treatments such as neuromodulation and biobehavioral therapy for both preventive and acute treatment. In this paper, we will review and summarize updated guideline for migraine treatment.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/42252)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.